Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Yuko Palesch and Lydia Foster.
Yuko Palesch
Connection Strength
0.821
Lydia Foster
  1. Endovascular Therapy Demonstrates Benefit over Intravenous Recombinant Tissue Plasminogen Activator Based on Repeatedly Measured National Institutes of Health Stroke Scale. Interv Neurol. 2017 Mar; 6(1-2):25-30.
    View in: PubMed
    Score: 0.142
  2. Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial. Stroke. 2015 May; 46(5):1321-7.
    View in: PubMed
    Score: 0.128
  3. Regional Differences in the Response to Acute Blood Pressure Lowering After Cerebral Hemorrhage. Neurology. 2021 02 02; 96(5):e740-e751.
    View in: PubMed
    Score: 0.047
  4. Late Neurological Deterioration after Acute Intracerebral Hemorrhage: A post hoc Analysis of the ATACH-2 Trial. Cerebrovasc Dis. 2020; 49(1):26-31.
    View in: PubMed
    Score: 0.045
  5. Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2019 05; 18(5):428-438.
    View in: PubMed
    Score: 0.042
  6. Clinical Outcomes Depending on Acute Blood Pressure After Cerebral Hemorrhage. Ann Neurol. 2019 01; 85(1):105-113.
    View in: PubMed
    Score: 0.041
  7. Blood Pressure-Attained Analysis of ATACH 2 Trial. Stroke. 2018 06; 49(6):1412-1418.
    View in: PubMed
    Score: 0.040
  8. Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III. J Am Heart Assoc. 2017 May 08; 6(5).
    View in: PubMed
    Score: 0.037
  9. Endovascular Therapy Is Effective and Safe for Patients With Severe Ischemic Stroke: Pooled Analysis of Interventional Management of Stroke III and Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands Data. Stroke. 2015 Dec; 46(12):3416-22.
    View in: PubMed
    Score: 0.033
  10. Endovascular revascularization results in IMS III: intracranial ICA and M1 occlusions. J Neurointerv Surg. 2015 Nov; 7(11):795-802.
    View in: PubMed
    Score: 0.031
  11. Evolution of practice during the Interventional Management of Stroke III Trial and implications for ongoing trials. Stroke. 2014 Dec; 45(12):3606-11.
    View in: PubMed
    Score: 0.031
  12. Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial. Radiology. 2014 Oct; 273(1):202-10.
    View in: PubMed
    Score: 0.030
  13. Drivers of costs associated with reperfusion therapy in acute stroke: the Interventional Management of Stroke III Trial. Stroke. 2014 Jun; 45(6):1791-8.
    View in: PubMed
    Score: 0.030
  14. Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):567-74.
    View in: PubMed
    Score: 0.030
  15. Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience. Stroke. 2014 May; 45(5):1408-14.
    View in: PubMed
    Score: 0.030
  16. Collaterals at angiography and outcomes in the Interventional Management of Stroke (IMS) III trial. Stroke. 2014 Mar; 45(3):759-64.
    View in: PubMed
    Score: 0.029
  17. Alberta Stroke Program early computed tomography score to select patients for endovascular treatment: Interventional Management of Stroke (IMS)-III Trial. Stroke. 2014 Feb; 45(2):444-9.
    View in: PubMed
    Score: 0.029
  18. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013 Mar 07; 368(10):893-903.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.